Anticancer Drugs Market size was valued at US$ 177.28 Bn. in 2021 and the total Anticancer Drugs Market revenue is expected to grow at 12 % from 2021 to 2029, reaching nearly US$ 438.95 Bn.
Anticancer Drugs Market Overview:Cancer is a major and growing global burden, reflecting an aging population and, to some extent, the performance of countries' healthcare systems. In certain countries, the lifetime chance of having cancer surpasses 50%, and the expenses of therapy, particularly pharmacotherapies, are skyrocketing. The cancer burden in the European Union (EU) was 3.1 million new cancer cases and 1.4 million cancer deaths in 2018, with direct cancer health expenses of EUR 103 billion, of which cancer drugs accounted for 31%. The Agency for Healthcare Research and Quality estimated the direct medical expenditures of cancer care in the United States in 2015 at more than USD 80 billion. Substantial improvements in cancer care have occurred in recent decades, owing to advancements in prevention, early detection, pharmacotherapies, and other treatment methods. Although cancer mortality in Europe climbed from 1.2 million in 1995 to 1.4 million in 2018, the rate of increase has slowed and fatalities in age groups under 65 years have decreased. It is expected that the five-year survival rates for the most prevalent cancer types rose in all European nations between 1995 and 2014. During the same period, five-year net survival improved in practically all seven cancer types in seven high-income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the United Kingdom). Between 1995-1999 and 2010-2014, the biggest recorded gains in five-year survival were 16.6 and 21.0 percentage points for colorectal cancer in Denmark, respectively. However, estimating the role of cancer drugs in these survival gains is difficult. Furthermore, since 2014, numerous cancer treatments that are now considered standard of care have been licensed. The Anticancer Drugs Market is segmented based on Drug Class, Indication and Region. The growth of various segments helps the report users in acquiring knowledge of the many growth factors expected to be prevalent throughout the market and develop different strategies to help identify core application areas and the gap in the target market. The report provides an in-depth analysis of the market and contains meaningful insights, facts, historical data, and statistically supported and industry-validated market statistics. It also includes estimates based on an appropriate set of assumptions and methodologies. To know about the Research Methodology :- Request Free Sample Report Covid-19 Impact: In late December, the coronavirus (COVID-19) was found in the Chinese city of Wuhan's Hubei province. A virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that spreads from person to person is the cause of the illness. Owing to international trade limitations on pharmaceutical items and chemicals, supply chains were interrupted. Additionally, COVID 19 is an infectious illness that causes flu-like symptoms like fever, coughing, and breathing difficulties. The COVID-19 pandemic has a significant influence on the most important sections of the market for cancer treatments by interfering with clinical trials and patient access to medications. The pandemic has a direct impact on the availability of anticancer drugs for cancer patients. In addition to making it challenging to administer chemotherapy and some other treatments outside of a clinic, the spread of the coronavirus has decreased patients' willingness and ability to participate in clinical trials for new medications. One of the biggest blows to the anticancer drug market has been the interference of COVID-19 with research and development of new treatments. However, after the COVID-19 pandemic, this condition is expected to change.
Anticancer Drugs Market Dynamics:Market Drivers: Increased Cancer Prevalence supports market growth. After cardiovascular diseases, cancer is now the second biggest cause of death owing to an increase in its incidence rate. This phenomena is caused by environmental variables such cigarette use, altered dietary habits, urbanisation, and prolonged postreproductive lifespan. For instance, the World Health Organization (WHO) estimates that there will be 30 million new instances of cancer globally by 2040, up from 21 million in 2021. Therefore, it is expected that throughout the forecast period, the rising incidence of cancer increases demand for anticancers medications globally. Furthermore, it is expected that in the forecast period, the global market benefit from the population's growing awareness of cancer. Strong drug pipeline present to promote growth opportunities The rate of advancement in cancer treatment is growing. Emerging from the research and development pipeline are a number of novel treatments that are frequently combined with other brand-new or current medications. A large number of pharmaceutical corporations are funding the development of new cancer treatments. For instance, Pfizer purchased Array BioPharma in June 2019 with the intention of growing its anticancer footprint and pipeline, starting with a melanoma combination medication that has been licenced and is currently undergoing testing for a type of metastatic colorectal cancer. This is expected to accelerate market growth, along with consumer desire for biosimilar and biologic products growing. Market Restraints: Adverse drug reactions, Strict Regulations, and Patent Expiration to hamper Market Growth Chemotherapy medications destroy cancer cells while harming healthy bodily cells as well. For the patients, this has a variety of negative side effects. Bone marrow suppression, gastrointestinal issues, neuropathies, hair loss, lethargy, and skin issues are among of the most typical adverse effects. As a result, the market's growth is being adversely affected by severe side effects of oncology medications. Other factors that are preventing the global market from growing throughout the Forecast period include strict government regulations, expensive medication, and patent expiration. Market Opportunities: The rise in risk factors for cancer, such as industrialization, sedentary lifestyles, and exposure to carcinogens, as well as attractive reimbursements, are some of the major reasons expected to drive the market growth of the anticancer drug market. The market for anticancer medications is growing significantly owing to rising awareness of early diagnosis and treatment. Other factors expected to help to the market growth of the anticancer drug market include the growing healthcare infrastructure, government efforts, and healthcare investments. In addition, rising out-of-pocket healthcare costs in both developing and developed economies, as well as the establishment of sizable cancer speciality hospitals, are expected to fuel the growth of the anticancer drug market. Another factor driving the global market for anti-cancer medications is the rising incidence of breast cancer and the improvements in survival rates. Recent Trends: Growing R&D Focus to Promote Uptake of Advanced Drug Therapies. Cancer patients are treated with the hopes of curing the illness, extending life, and enhancing quality of life. Immune cells are crucial to the development of tumours. Consequently, encouraging immune responses against cancers is an appealing therapeutic and preventative approach. Therefore, leading market players are making investments in immunotherapy research and development to treat a variety of cancers. For instance, in March, the National Cancer Center of Japan and the Fujifilm Corporation jointly announced the start of a research effort for a novel cancer immunotherapy employing a liposome formulation. Owing to its success in providing effective treatment that improves patient outcomes, immunotherapy is more widely used nowadays. As a result, this is helping the market growth.
Anticancer Drugs Market Segment Analysis:Based on Drug Class, The Targeted therapy segment is expected to grow at the highest CAGR during the forecast period. The market offers cytotoxic pharmaceuticals, targeted drugs, hormonal drugs, and other drugs based on drug class. The intended In 2019, the pharmaceuticals market category dominated the global market for anticancer drugs. Either the chemotherapy. While limiting unintended side effects on healthy cells, focused therapy targets the disease. This causes it to be more widely used than the other medications on the market, which results in its domination. Additionally, the increased number of product approvals and pipeline prospects for this category are expected to boost the growth of the market during the expected time frame. For instance, Pfizer introduced three anticancer products in January 2020.Treatments with monoclonal antibodies called rituximab-pwr (Ruxience), bevacizumab-bvzr (Zirabev), and market for trastuzumab-qyyp (Trazimera). Based on Indication, The Breast Cancer segment is expected to grow at the highest CAGR during the forecast period. The market for anticancer drugs are divided into categories for breast cancer, lung cancer, stomach cancer, colorectal cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer and others based on indication. Breast cancer is becoming more common, awareness is rising, there are more breast cancer therapies being introduced, and major R&D investments by leading market participants are some of the factors driving its quicker growth throughout the forecast period. For instance, Emcure Pharmaceuticals introduced the generic Eribilin, a therapy for metastatic breast cancer, in India in April 2019. On the other hand, the others category, which includes many other cancer kinds like bladder cancer, kidney cancer, thyroid cancer, uterine cancer, pancreatic cancer, lymphoma, etc., accounts for the largest proportion in 2019.
Anticancer Drugs Market Regional Insights:North America accounted as a largest market for the anticancer drugs market. Owing to a large patient population, the presence of significant key players, the ease with which drugs are made available, the strength of the healthcare infrastructure, the favourable reimbursement policies in the healthcare system, the higher number of research, development, and innovation activities, and the higher adoption of advanced therapeutics are all factors that are expected to maintain its dominance from 2021 to 2029. However, due to an increase in the number of people with cancer and a rise in awareness of various malignancies, Asia-Pacific is expected to grow at the highest CAGR. Owing to growing demand, the global market for anticancer medications has become more attractive owing to an increase in disease prevalence in emerging regions. Due to unmet demands and the high mortality rates from cancer in the region, China and India are the two countries driving a substantial revenue market. The objective of the report is to present a comprehensive analysis of the Anticancer Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Anticancer Drugs Market dynamics, structure by analyzing the market segments and project the Anticancer Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Anticancer Drugs Market make the report investor’s guide.
Anticancer Drugs Market Scope: Inquire before buying
Anticancer Drugs Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 177.28 Bn. Forecast Period 2022 to 2029 CAGR: 12 % Market Size in 2029: US $ 438.95 Bn. Segments Covered: by Drug Class • Targeted Therapy • Chemotherapy • Immunotherapy • Hormonal Therapy by Indication • Breast Cancer • Lung Cancer • Stomach Cancer • Colorectal Cancer • Prostate Cancer • Liver Cancer • Esophagus Cancer • Cervical Cancer • Kidney Cancer • Bladder Cancer • Other Cancers
Anticancer Drugs Market, by Region• North America • Europe • Asia Pacific • Middle East and Africa • South America
Anticancer Drugs Market Key Players• Abbott Laboratories • AbbVie • Amgen • Astellas Pharma • AstraZeneca • Aurora Biophama • F. Hoffmann-La Roche AG • Novartis AG • Boehringer Ingelheim • Bristol-Myers Squibb Company • Eli Lilly • Fresenius Kabi • Gilead • GlaxoSmithKline (GSK) • Grifols • Merck & Co., Inc. • Johnson & Johnson • Jounce Therapeutics • Pfizer Inc • Celgene Corporation FAQs: 1. Which is the potential market for the Anticancer Drugs Market in terms of the region? Ans. In North America region, the growing business and educational sectors are expected to help drive the use of collaborative screens. 2. What are the opportunities for new market entrants? Ans. The key opportunity in the market is new initiatives from governments that provide funding for Anticancer Drugs Markets in educational institutes 3. What is expected to drive the growth of the Anticancer Drugs Market in the forecast period? Ans. A major driver in the Anticancer Drugs Market is the prevalence of work from home and remote collaboration created by the COVID-19 pandemic 4. What is the projected market size & growth rate of the Anticancer Drugs Market? Ans. Anticancer Drugs Market size was valued at US$ 158.29 Billion in 2020 and the total Anticancer Drugs Market revenue is expected to grow at 12 % through 2021 to 2029, reaching nearly US$ 438.95 Billion. 5. What segments are covered in the Anticancer Drugs Market report? Ans. The segments covered are Drug Class, Indication, and Region.
1. Global Anticancer Drugs Market Size: Research Methodology 2. Global Anticancer Drugs Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Anticancer Drugs Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Anticancer Drugs Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Anticancer Drugs Market Size Segmentation 4.1. Global Anticancer Drugs Market Size, by Drug Class (2021-2029) • Targeted Therapy • Chemotherapy • Immunotherapy • Hormonal Therapy 4.2. Global Anticancer Drugs Market Size, by Indication (2021-2029) • Breast Cancer • Lung Cancer • Stomach Cancer • Colorectal Cancer • Prostate Cancer • Liver Cancer • Esophagus Cancer • Cervical Cancer • Kidney Cancer • Bladder Cancer • Other Cancers 5. North America Anticancer Drugs Market (2021-2029) 5.1. North America Anticancer Drugs Market Size, by Drug Class (2021-2029) • Targeted Therapy • Chemotherapy • Immunotherapy • Hormonal Therapy 5.2. North America Anticancer Drugs Market Size, by Indication (2021-2029) • Breast Cancer • Lung Cancer • Stomach Cancer • Colorectal Cancer • Prostate Cancer • Liver Cancer • Esophagus Cancer • Cervical Cancer • Kidney Cancer • Bladder Cancer • Other Cancers 5.3. North America Anticancer Drugs Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Anticancer Drugs Market (2021-2029) 6.1. European Anticancer Drugs Market, by Drug Class (2021-2029) 6.2. European Anticancer Drugs Market, by Indication (2021-2029) 6.3. European Anticancer Drugs Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Anticancer Drugs Market (2021-2029) 7.1. Asia Pacific Anticancer Drugs Market, by Drug Class (2021-2029) 7.2. Asia Pacific Anticancer Drugs Market, by Indication (2021-2029) 7.3. Asia Pacific Anticancer Drugs Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Anticancer Drugs Market (2021-2029) 8.1. Middle East and Africa Anticancer Drugs Market, by Drug Class (2021-2029) 8.2. Middle East and Africa Anticancer Drugs Market, by Indication (2021-2029) 8.3. Middle East and Africa Anticancer Drugs Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Anticancer Drugs Market (2021-2029) 9.1. South America Anticancer Drugs Market, by Drug Class (2021-2029) 9.2. South America Anticancer Drugs Market, by Indication (2021-2029) 9.3. South America Anticancer Drugs Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Abbott Laboratories 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. AbbVie 10.3. Amgen 10.4. Astellas Pharma 10.5. AstraZeneca 10.6. Aurora Biophama 10.7. F. Hoffmann-La Roche AG 10.8. Novartis AG 10.9. Boehringer Ingelheim 10.10. Bristol-Myers Squibb Company 10.11. Eli Lilly 10.12. Fresenius Kabi 10.13. Gilead 10.14. GlaxoSmithKline (GSK) 10.15. Grifols 10.16. Merck & Co., Inc. 10.17. Johnson & Johnson 10.18. Jounce Therapeutics 10.19. Pfizer Inc 10.20. Celgene Corporation